Cargando…

SAT471 Hearing-Related Adverse Events in Teprotumumab Oncology Clinical Trials

Disclosure: T.J. Smith: Consulting Fee; Self; Horizon Therapeutics plc, Viridian, Lundbeck. Other; Self; US patents covering the use of IGF-1 receptor inhibitors in TED which are held by UCLA and the Lundquist Institute. Q. Fu: Employee; Self; Horizon Therapeutics plc. Stock Owner; Self; Horizon The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Terry J, Fu, Qianhong, Holt, Robert J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553700/ http://dx.doi.org/10.1210/jendso/bvad114.1945

Ejemplares similares

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials
por: Kahaly, George J, et al.
Publicado: (2023)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
por: Douglas, Raymond S, et al.
Publicado: (2022)

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

SAT-471 A Rare Case of Pretibial Myxedema Preceding Graves’ Hyperthyroidism
por: Bao, Ginny W, et al.
Publicado: (2020)

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)
por: Xin, Yan, et al.
Publicado: (2020)

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)

MON-471 The Broken Heart That Hid Behind the Goiter
por: Newman, Samantha Kass, et al.
Publicado: (2020)

SAT466 Inactive Thyroid Eye Disease Patient Journey
por: Cockerham, Kimberly, et al.
Publicado: (2023)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

FRI554 Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab
por: Marta Niedzialkowska, Ewelina, et al.
Publicado: (2023)

SAT-418 Finding the Needles in the Haystack: Harnessing the Electronic Health Record to Find Thyroid Immune Related Adverse Events
por: Quandt, Zoe, et al.
Publicado: (2020)

SAT-411 Vitamin D Levels and Risk of Thyroid Immune Related Adverse Events in Patients on Immune Checkpoint Inhibitors
por: Newman, Samantha Kass, et al.
Publicado: (2020)

SAT-416 Novel Autoantibodies for Thyroid-Specific Transcriptional Factors in Patients with Immune-Related Adverse Events Involving the Thyroid Gland
por: Yamauchi, Ichiro, et al.
Publicado: (2020)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

SAT453 Endocrine Related Adverse Events Of Immune Checkpoint Inhibitors In Cancer Patients Visiting Tertiary Care Center In Saudi Arabia
por: Mohammed Alqahtani, Ali, et al.
Publicado: (2023)

ODP471 Concomitant Metastatic Papillary Thyroid Cancer and Graves’ Disease Presenting as Thyroid Storm
por: Parihar, Aisha, et al.
Publicado: (2022)

FRI471 Regulation Of Adult Thyroid Hormone Homeostasis By Early Postnatal Hyperthyroidism In Male Mice
por: Kovári, Dóra, et al.
Publicado: (2023)

Rapidly Progressive Cognitive Decline and Varicella Zoster Blisters Associated With Teprotumumab in 2 Patients With Graves’ Orbitopathy
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

PSAT355 A Case Report Identifying Graves’ Ophthalmopathy in a Myasthenia Gravis Crisis and Response to Teprotumumab
por: Zia, Abdul, et al.
Publicado: (2022)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT-584 Pembrolizumab-Related Graves' Disease: A Rare Adverse Effect of an Anti-PD-1 Antibody Cancer Immunotherapy
por: Narayen, Garima, et al.
Publicado: (2019)

OR26-02 VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor In Development For Thyroid Eye Disease (TED), Binds To A Distinct Epitope From Teprotumumab
por: Bedian, Vahe, et al.
Publicado: (2023)

SAT-424 Assessing Content Validity of the Graves’ Ophthalmopathy Quality of Life Questionnaire (GO-QOL) in the United States
por: Stan, Marius N, et al.
Publicado: (2020)

SAT-504 Delayed Hypersensitivity to Levothyroxine, and Oral Desensitization
por: Sandooja, Rashi, et al.
Publicado: (2020)

SAT-611 Abdominal Goiter
por: Bedoya, Pablo, et al.
Publicado: (2019)

SAT-519 Armour Thyroid and Liothyronine Combination Potentiated Thrombosis
por: Shin, Tai Ho, et al.
Publicado: (2020)

SAT-514 Nivolumab Related Primary Hypothyroidism: 3 Years of Follow-Up
por: Baby, Ann Pia, et al.
Publicado: (2020)

Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors
por: Muir, Christopher Alan, et al.
Publicado: (2021)

SAT-494 An Unusual Presentation of Hypothyroidism
por: Sukumaran, Anju
Publicado: (2020)

SAT-509 Sudden Onset of Malabsorption
por: Mroueh, Gabriela, et al.
Publicado: (2020)

SAT539 Thyroid Cancer Presenting as Aspiration Pneumonia
por: Aslam, Sadia, et al.
Publicado: (2023)

SAT-558 Tsh Modulation Of Bone Biology - Further Evidence From A Recombinant Tsh-β Variant.
por: Baliram, Ramkumarie, et al.
Publicado: (2019)

SAT-604 Immunoglobulin G4-related Disease In A Patient With Graves' Disease
por: Ozgen Saydam, Basak, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ukjbenpb8773d8lidbrfumg91v